Zoetis (ZTS) Falls -31% in 30 Days: Earnings Miss and Guidance Cut Weigh on Shares
Key Takeaways
- Zoetis Inc. (ZTS) stock fell approximately 31% over the past 30 days, driven primarily by disappointing first-quarter 2026 earnings results and a lowered full-year guidance.
- Over the past quarter, the stock declined around 37%, reflecting broader concerns about U.S. companion animal demand softness that intensified after the earnings release.
- The company reported first-quarter revenue of $2.3 billion, up 3% year-over-year but flat on an organic operational basis, missing analyst expectations in key metrics.
- Management reduced 2026 adjusted earnings per share guidance to a range of $6.85 to $7.00, citing weaker U.S. pet spending and competitive pressures.
- Sector and macroeconomic factors, including price sensitivity among pet owners and fewer veterinary visits, amplified negative market sentiment.
Zoetis's Position in the Animal Health Market
Zoetis Inc. is the world’s leading animal health company, focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for livestock and companion animals. Its core business model centers on providing innovative solutions that improve animal health, productivity, and well-being, serving veterinarians, farmers, and pet owners globally. The company operates in the animal health industry, where it holds a strong competitive position through a diversified portfolio spanning companion animal (pets) and livestock segments, with significant exposure to the U.S. market. These fundamentals help explain recent stock behavior, as softness in U.S. companion animal demand directly pressured results and investor confidence.
Stock Performance: -31% Over 30 Days and -37% Over the Quarter
Over the last 30 days, ZTS stock declined approximately 31%, moving from a closing price near $117.52 to $81.32. The movement was sharply negative and event-driven rather than gradual, with most of the decline occurring in a single session following earnings. The stock traded in a relatively narrow range before the catalyst but experienced high volatility afterward.
Over the last quarter, the stock fell approximately 37%, declining from levels near $128.78 to the recent close of $81.32. Performance was range-bound early in the period before the steep drop, reflecting sustained pressures that culminated in the earnings disappointment.
The Earnings Catalyst Behind the Recent Sell-Off
The primary catalyst was Zoetis Inc.’s first-quarter 2026 earnings release on May 7, 2026. The company reported adjusted diluted earnings per share of $1.53, missing consensus estimates, and revenue of $2.3 billion that fell short of expectations on an organic operational basis. Management lowered full-year 2026 guidance, projecting adjusted earnings per share between $6.85 and $7.00 and citing softer U.S. pet demand, higher price sensitivity, and reduced veterinary visits. This led to an immediate sharp sell-off, with shares dropping over 20% on the day and continuing lower amid ongoing concerns. Analyst commentary highlighted that the quarter appeared “worse than it seems” due to persistent macro and competitive dynamics in the companion animal segment.
Broader Pressures That Built Over the Quarter
Broader weakness in U.S. companion animal spending weighed on ZTS throughout the quarter, with international segments showing relatively stronger growth. Macroeconomic conditions, including inflation-driven caution among pet owners and competitive pressures in the animal health space, created a challenging environment. Institutional investor sentiment shifted negatively as early signs of demand softness emerged, culminating in the guidance cut that confirmed these trends. The cumulative impact of these factors produced the sustained downward trajectory observed over the three-month period.
Reviewing Automated Trading Strategies
When evaluating how stocks like this move in volatile periods, I sometimes look at Tickeron’s Trending AI Robots page. It highlights a selection of high-performing AI trading bots from hundreds available on the platform, showing different strategies, timeframes, and metrics. This neutral overview can give a sense of how automated approaches are currently positioned across various market conditions.
What Investors Should Watch Next
Investors should monitor upcoming quarterly earnings releases for updates on revenue trends and guidance revisions. Key factors include U.S. companion animal demand indicators, such as veterinary visit volumes and pet owner spending patterns. Broader macroeconomic conditions, including inflation and consumer confidence, along with competitive developments in the animal health sector, will remain important. Strategic initiatives, such as new product launches or portfolio adjustments, could also influence sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ZTS turns negative, indicating new downward trend
ZTS saw its Momentum Indicator move below the 0 level on June 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In of the 84 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZTS broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZTS's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ZTS just turned positive on May 26, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 227 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.204) is normal, around the industry mean (78.593). P/E Ratio (12.903) is within average values for comparable stocks, (97.010). Projected Growth (PEG Ratio) (1.886) is also within normal values, averaging (1.586). Dividend Yield (0.026) settles around the average of (0.034) among similar stocks. P/S Ratio (3.613) is also within normal values, averaging (95.524).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pet medication company
Industry PharmaceuticalsGeneric
Advertisement